Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Photoinduced Photosensitizer-Antibody Conjugates Kill HIV Env-Expressing Cells, Also Inactivating HIV

Full text
Author(s):
Sadraeian, Mohammad [1] ; da Cruz, Edgar Ferreira [2] ; Boyle, Ross W. [3] ; Bahou, Calise [4] ; Chudasama, Vijay [4] ; Ramos Janini, Luiz Mario [2] ; Diaz, Ricardo Sobhie [2] ; Guimaraes, Francisco E. G. [1]
Total Authors: 8
Affiliation:
[1] Sao Carlos Inst Phys, BR-13560970 Sao Carlos, SP - Brazil
[2] Univ Fed Sao Paulo, Lab Retrovirol, Sao Paulo - Brazil
[3] Univ Hull, Dept Chem, Kingston Upon Hull HU6 7RX, N Humberside - England
[4] UCL, Dept Chem, London WC1H 0AJ - England
Total Affiliations: 4
Document type: Journal article
Source: ACS OMEGA; v. 6, n. 25, p. 16524-16534, JUN 29 2021.
Web of Science Citations: 0
Abstract

HIV-infected cells persist for decades in patients administered with antiretroviral therapy (ART). Meanwhile, an alarming surge in drug-resistant HIV viruses has been occurring. Addressing these issues, we propose the application of photo-immunotherapy (PIT) against not only HIV Env-expressing cells but also HIV. Previously, we showed that a human anti-gp41 antibody (7B2) conjugated to cationic or anionic photosensitizers (PSs) could specifically target and kill the HIV Env-expressing cells. Here, our photolysis studies revealed that the binding of photoimmunoconjugates (PICs) on the membrane of HIV Env-expressing cells is sufficient to induce necrotic cell death due to physical damage to the membrane by singlet oxygen, which is independent of the type of PSs. This finding persuaded us to study the virus photoinactivation of PICs using two HIV-1 strains, X4 HIV-1 NL4-3 and JR-CSF virus. We observed that the PICs could destroy the viral strains, probably via physical damage on the HIV envelope. In conclusion, we report the application of PIT as a possible dual-tool for HIV immunotherapy and ART by killing HIV-expressing cells and cell-free HIV, respectively. (AU)

FAPESP's process: 13/11323-5 - Multi interventional study exploring HIV-1 residual replication: a step towards HIV-1 eradication and sterilizing cure
Grantee:Ricardo Sobhie Diaz
Support Opportunities: Regular Research Grants
FAPESP's process: 13/07276-1 - CEPOF - Optics and Photonic Research Center
Grantee:Vanderlei Salvador Bagnato
Support Opportunities: Research Grants - Research, Innovation and Dissemination Centers - RIDC